Overview
- OKAVA Pharmaceuticals launched the MEOW‑1 study evaluating OKV‑119, a subdermal implant that uses Vivani Medical’s NanoPortal technology to deliver exenatide.
- The trial is registered with the American Veterinary Medical Association Clinical Trials Registry and is being conducted under an FDA Center for Veterinary Medicine Investigational New Animal Drug application.
- Up to 50 overweight cats are slated for enrollment with weight and health assessments at three and six months, with results anticipated in summer 2026.
- If efficacy and safety are demonstrated, OKAVA plans a larger feline study and a follow‑on canine trial before seeking FDA approval in 2027–2028.
- A report claiming the study had already been completed conflicts with company materials and other outlets that describe the trial as newly underway.